| NCT ID | NCT05633303 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Barts & The London NHS Trust |
| Condition | Atrium; Fibrillation |
| Study Type | INTERVENTIONAL |
| Enrollment | 160 participants |
| Start Date | 2022-10-14 |
| Primary Completion | 2027-10-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 160 participants in total. It began in 2022-10-14 with a primary completion date of 2027-10-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Atrial fibrillation (AF) is the most common arrhythmia with an expected rise in prevalence over the next decade. Catheter ablation is a safe treatment option in eliminating AF however, success rates still remains variable. Existing strategies do not take into account the differences in AF perpetuation mechanisms beyond the pulmonary veins (PVs) due to the underlying substrate. Here, I will investigate the differences in persistent AF mechanisms due to the underlying substrate and utilise these findings to generate AF mechanism specific ablation strategies. I have defined a new metric, rate-dependent conduction velocity (RDCV) slowing that has shown to correlate with sites of re-entry activity in AF. In this study, techniques and methods will be developed to measure RDCV slowing sites. The impact autonomic modulation has on AF mechanisms and CV dynamics will also be assessed. The hypothesis is that a combination of structural, electrical and autonomic remodelling play an important mechanistic role in persistent AF and ablation strategies adapted to target these will result in greater procedural success rate. The study findings have the potential to improve the success rate of catheter ablation in persistent AF thereby improve patient wellbeing and reduce the cost burden of AF treatment.
Eligibility Criteria
Inclusion Criteria: * Patients undergoing catheter ablation for persistent AF (\<24 months AF duration and no previous left atrial ablation). * Able to provide informed consent Exclusion Criteria: * Unwillingness to sign consent * Age \<18 years * Contraindications for catheter ablation procedure
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05633303 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Atrium; Fibrillation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05633303 currently recruiting?
Yes, NCT05633303 is actively recruiting participants. Contact the research team at shohreh.honarbakhsh@nhs.net for enrollment information.
Where is the NCT05633303 trial being conducted?
This trial is being conducted at London, United Kingdom.
Who is sponsoring the NCT05633303 clinical trial?
NCT05633303 is sponsored by Barts & The London NHS Trust. The trial plans to enroll 160 participants.